Elite Pharmaceuticals, Inc.
165 Ludlow Avenue
Northvale, NJ 07647
Tel: (201) 750-2646
April 14, 2009
AS FILED ON EDGAR AND
VIA FACSIMILE
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E., Mail Stop 6010
Washington, DC 20549
Attn: Sasha Singh Parikh, Staff Accountant
|
Re: |
Elite Pharmaceuticals, Inc. |
Dear Ms. Parikh:
On behalf of Elite Pharmaceuticals, Inc., a Delaware corporation (the “Company”), please be advised that the undersigned has received and read your letter, dated March 16, 2009, with regard to Item 4.01 of the Current Report on Form 8-K/A filed by the Company with the United States Securities and Exchange Commission (the “Commission”) on March 12, 2009.
The Company hereby acknowledges that:
• |
the Company is responsible for the adequacy and accuracy of the disclosure in the filing; |
• |
staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and |
• |
the Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. |
Of course, if you should require any additional information or clarification, please do not hesitate to contact the undersigned at (201) 367-7860.
Securities and Exchange Commission
April 14, 2009
Re: Elite Pharmaceuticals, Inc.
Page 2 of 2
Your assistance in this matter is greatly appreciated.
Sincerely,
ELITE PHARMACEUTICALS, INC.
By: /s/ Chris Dick
Name: |
Chris Dick |
Title: |
Chief Operating Officer and |
cc: Mark Gittelman, Chief Financial Officer